Objective: To discuss the effect of sequential therapies of Shuxuetong injection and Danlou pills on the blood platelet function and risk scores of global registration of acute coronary events (GRACE) in treating acute coronary syndrome (phlegm and blood stasis type). Method: Ninety eligible patients with acute coronary syndrome (ACS) were randomly divided into control group (45 cases) and observation group (45 cases) by random number table. Both groups received percutaneous coronary intervention (PCI) operation. After the operation

patients in control group received treatments of anti-ischemia

lipid-lowering

antiplatelet and anticoagulation

orally taking aspirin enteric-coated tablets

300 mg for first load dose

and 100 mg/time

1 time/day for maintenance treatment

clopidogrel bisulfate tablets

300 mg for first load dose

and 75 mg/time

1 time/day for maintenance dose. The treatment course was 10 weeks. Based on the treatment of control group

patients in observation group received additional ①Shuxuetong injection for intravenous drip

6 mL/time

1time/day

with a treatment course of 2 weeks.② Danlou pills

5 pills/time

3 times/day

with a treatment course of 8 weeks. Scores of phlegm and blood stasis were graded before treatment

at Week 2 and week 10 after treatment.GRACE was evaluated at time of admission and discharge. Before treatment and at Week 2 and week 10 after treatment

levels of platelets counts (PLT)

mean platelet volume (MPV)

platelet distribution width (PDW)

plateletcrit (PCT) of platelet parameters and platelet aggregation (PAR)

platelet-selectin (P-selectin)

von willebrand factor (vWF) and GMP-140 platelets surface were detected respectively. Result: At week 2 and week 10 after treatment

scores of phlegm and blood stasis were gradually decreased in both groups (P<0.01)

and the scores in observation group were lower than those in control group (P<0.01). At the time of discharge

GRACE score in observation group was lower than that in control group (P<0.01). And at week 2 and week 10 after treatment

levels of PLT

MPV and PDW were decreased in both groups (P<0.05

P<0.01). At week 2 after treatment

levels of MPV and PDW in observation group were decreased more obviously (P<0.05). Levels of PAR

P-selectin

vWF and GMP-140 in observation group were lower than those in control group at week 2 and week 10 after treatment group (P<0.01). Conclusion: sequential therapies of Shuxuetong injection and Danlou pills can inhibit platelet activation in patients with acute coronary syndrome after PCI

reduce thrombosis risk and scores of phlegm and blood stasis and GRACE

so it is helpful to improve prognosis for the patients.